The Relationship Between Human Effector and Memory T Cells Measured by Ex Vivo and Cultured ELISPOT Following Recent and Distal Priming
Overview
Authors
Affiliations
Maintenance of T-cell responses is an essential feature in protection from many infectious diseases that must be harnessed in vaccination. The relationship between effector T-cell responses and more durable and highly proliferative T-cell memory, particularly in humans, is not well understood. In this study, effector T-cell responses were measured by overnight ex vivo interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot-forming cell assay (ELISPOT), whereas memory T cells were measured by 10-day culture followed by IFN-gamma ELISPOT (cultured ELISPOT). We observed a significant correlation between IFN-gamma responses to CD4-stimulatory, but not to CD8-stimulatory, recall antigens measured by these assays, suggesting a divergence in regulation. In vaccine trial participants who received a prime-boost vaccination regimen comprising malaria antigens delivered by poxviruses, there was a correlation between ex vivo and cultured responses on day 7, but not 3 months post-vaccination, with the ratio of cultured : ex vivo response increasing over time. To compare responses revealed by cultured ELISPOT in more detail, tetramers comprising viral recall antigens were used to ascribe effector-memory and central-memory T-cell phenotypes through CCR7 and CD62L costaining. For CD8(+) responses the effector phenotype decreased during the initial culture period and memory populations remained high within the resulting 20-fold to 50-fold increased IFN-gamma-secreting or tetramer(+) population. This was less marked for CD4(+) responses, which had higher starting memory phenotype. Depletion of these central-memory T-cell populations generally ablated responses in cultured ELISPOT and reduced ex vivo responses. This study highlights differences between CD4(+) and CD8(+) effector and memory T cells, and the more complex phenotype of CD4(+) T cells.
Aleith J, Bergmann-Ewert W, Muller-Hilke B Eur J Immunol. 2025; 55(3):e202451193.
PMID: 40071676 PMC: 11898573. DOI: 10.1002/eji.202451193.
Talpin A, Maia A, Carpier J, Kulakowski G, Aubergeon L, Kervevan J J Immunother Cancer. 2025; 13(2).
PMID: 39979071 PMC: 11842988. DOI: 10.1136/jitc-2024-010192.
de Goer de Herve M, Dekeyser M, Hendel-Chavez H, Maillart E, Labeyrie C, Adams D Front Immunol. 2024; 15:1416074.
PMID: 39086476 PMC: 11289500. DOI: 10.3389/fimmu.2024.1416074.
Taus E, Shino M, Ibarrondo F, Hausner M, Hofmann C, Yang O J Transl Med. 2023; 21(1):374.
PMID: 37291575 PMC: 10248978. DOI: 10.1186/s12967-023-04234-z.
Taus E, Hofmann C, Ibarrondo F, Gong L, Hausner M, Fulcher J Front Immunol. 2023; 14:1100594.
PMID: 36860850 PMC: 9968837. DOI: 10.3389/fimmu.2023.1100594.